Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Vaso-occlusion contributes significantly to morbidity in sickle cell disease (SCD).
Vaso-occlusive painful episodes (VOE) are common and debilitating, causing the majority of
emergency department visits. Currently efforts to treat painful episodes with use of
non-steroidal pain relievers and intravenous narcotics offer symptomatic relief only, without
targeting the underlying mechanisms of vaso-occlusion.Investigators have found that an
arginine deficiency and low NO bioavailability occurs during painful events in SCD. Since
arginine is the obligate substrate for NO production, and an acute deficiency is associated
with VOE, investigators hypothesized that arginine supplementation may be a safe and
beneficial treatment for sickle cell pain.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland UCSF Benioff Children's Hospital Oakland